Feasibility and Safety of IMP321 for Advanced Stage Solid Tumors
Status:
Recruiting
Trial end date:
2024-06-30
Target enrollment:
Participant gender:
Summary
This phase I trial aims to investigate a potential enhancement of IMP321 immune-activating
effects by new routes of administration: direct injection of IMP321 into the tumor tissue;
intra-peritoneal therapy; combination of chemotherapy and/or immunotherapy/targeted therapy
with active immunotherapy
Phase:
Phase 1
Details
Lead Sponsor:
Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest Krankenhaus Nordwest